Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Gordon Srkalovic"'
Autor:
Adam M. Brufsky, Midas Kuilman, Rita Mukhtar, Denise M. Wolf, Christina Yau, Joyce O’Shaughnessy, Cathy Graham, Vijayakrishna K. Gadi, Pat Whitworth, Alexander Hindenburg, Ian Grady, Gordon Srkalovic, Kent Hoskins, Ajay Dhakal, Cynthia Ma, Natasha Hunter, Jennifer Crozier, Blanche Mavromatis, Lorenza Mittempergher, Christine Finn, Shraddha Modh, Erin B. Yoder, Patricia Dauer, Andrea Menicucci, Bas van der Baan, William Audeh, Laura J. Esserman
Publikováno v:
Cancer Research. 83:PD9-08
BACKGROUND: Immune checkpoint inhibitors in combination with chemotherapy have demonstrated an improvement of pathologic complete response (pCR) in patients with HR-HER2- and MammaPrint (MP) High Risk, HR+HER2- tumors in the I-SPY2 TRIAL. However, no
Autor:
Thomas Olencki, Paul Elson, Tarek Mekhail, Thomas E. Hutson, Ronald M. Bukowski, David M. Peereboom, Robert Pelley, Gordon Srkalovic, G. Thomas Budd
Publikováno v:
Cancer. 97:170-178
BACKGROUND A Phase I study using weekly docetaxel and gemcitabine was conducted to investigate toxicity; to determine the maximum tolerated dose (MTD) of each agent; and, in a preliminary fashion, to determine the antitumor activity of the combinatio
Autor:
Ruben Niesvizky, David T. Siegel, Bart Barlogie, David Irwin, S. Vincent Rajkumar, Steven Limentani, Sundar Jagannath, Gordon Srkalovic M.D., Elizabeth Trehu, Raymond Alexanian, Dixie L. Esseltine, James R. Berenson, Melissa Alsina, Kenneth Anderson, Seema Singhal, David P. Schenkein, Paul G. Richardson
Publikováno v:
Cancer. 104(10)
Background Bortezomib, a first-in-class proteasome inhibitor, is active with manageable toxicities in relapsed and/or refractory myeloma. Methods Bortezomib 1.0 or 1.3 mg/m2 was administered Days 1, 4, 8, and 11 every 21 days for up to 8 cycles to pa
Autor:
James R. Berenson, Sundar Jagannath, Bart Barlogie, David T. Siegel, Raymond Alexanian, Paul G. Richardson, David Irwin, Melissa Alsina, S. Vincent Rajkumar, Gordon Srkalovic, Seema Singhal, Steven Limentani, Ruben Niesvizky, Dixie L. Esseltine, Elizabeth Trehu, David P. Schenkein, Kenneth Anderson
Publikováno v:
Cancer (0008543X); Nov2005, Vol. 104 Issue 10, p2141-2148, 0p